Search research articles
Contact Us
Filters
Showing results (281-290 of 362) with videos related to
Page
of 37
Sort By:
The Lancet. Oncology
|
November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Rolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
Clinical and Translational Radiation Oncology
|
March 11, 2026
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy
Andrea R Filippi, Jair Bar, Daniel C Christoph, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Solange Peters, Luis G Paz-Ares, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2014
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project
Fiona H Blackhall, Solange Peters, Lukas Bubendorf, et al.
British Journal of Cancer
|
January 13, 2026
Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples
Markus Ball, Susanne Beck, Darius Wlochowitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 2026
Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project
Miguel A Molina-Vila, Zoi Tsourti, Katerina Vervita, et al.
British Journal of Cancer
|
March 2, 2026
Correction: Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples
Markus Ball, Susanne Beck, Darius Wlochowitz, et al.
Revue Medicale Suisse
|
January 20, 2023
[Oncology: what's new in 2022]
Tu Nguyen-Ngoc, Karim Abdelhamid, Nils Degrauwe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Nicolas Girard, Jair Bar, Pilar Garrido, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Page
of 37
Search research articles
Search
Showing results (281-290 of 362) with videos related to
Sort By:
Page
of 37
The Lancet. Oncology
|
November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Rolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
Clinical and Translational Radiation Oncology
|
March 11, 2026
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy
Andrea R Filippi, Jair Bar, Daniel C Christoph, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Solange Peters, Luis G Paz-Ares, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2014
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project
Fiona H Blackhall, Solange Peters, Lukas Bubendorf, et al.
British Journal of Cancer
|
January 13, 2026
Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples
Markus Ball, Susanne Beck, Darius Wlochowitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 2026
Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project
Miguel A Molina-Vila, Zoi Tsourti, Katerina Vervita, et al.
British Journal of Cancer
|
March 2, 2026
Correction: Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples
Markus Ball, Susanne Beck, Darius Wlochowitz, et al.
Revue Medicale Suisse
|
January 20, 2023
[Oncology: what's new in 2022]
Tu Nguyen-Ngoc, Karim Abdelhamid, Nils Degrauwe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Nicolas Girard, Jair Bar, Pilar Garrido, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Page
of 37